NOTE 4.  Balance Sheet Components

Cash, cash equivalents and investments consisted of the following (in thousands):

As of June 30, 2026 and December 31, 2025, all investments were available-for-sale debt securities with remaining maturities of 12 months or less. As of  June 30, 2026 and  December 31, 2025, the Company held 11 and 4 securities, respectively, in an unrealized loss position for 12 months or less. Interest receivable for both   June 30, 2026 and December 31, 2025, was $0.2 million and is recorded as a component of prepaid expenses and other current assets on the condensed consolidated balance sheets.

At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Factors considered when evaluating available-for-sale investments for impairment include the severity of the impairment, changes in underlying credit ratings, the financial condition of the issuer, the probability that the scheduled cash payments will continue to be made and the Company’s intent and ability to hold the investment until recovery of the amortized cost basis. The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs.

As of  June 30, 2026 and December 31, 2025, there were no material declines in the market value of the Company’s available-for-sale investments due to credit-related factors. The Company does not intend to sell the investments, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis. As of  June 30, 2026 and December 31, 2025, no allowance for credit losses was recorded and the Company did not recognize any impairment losses related to investments.

As of  June 30, 2026, accounts receivable consisted of $11,000 of royalty receivable. As of  December 31, 2025, accounts receivable of $14.6 million consisted of $14.2 million of government contract receivables from HHS BARDA and $0.3 million royalty receivable. See Note 5.

The Company has provided no allowance for credit losses as of  June 30, 2026 and December 31, 2025 based on historical collection experience, customer creditworthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that  may affect a customer’s ability to pay.

Unbilled receivable, which was earned and not yet billed, consists of government contracts from HHS BARDA of $47.0 million and $36.8 million as of June 30, 2026 and December 31, 2025, respectively, as detailed in Note 5.

Prepaid expenses and other current assets consist of the following (in thousands):

As of June 30, 2026 there was a significant concentration by one contract research organization (“CRO”), which represented 51% of the Company’s total prepaid expenses balance. As of  December 31, 2025, there was a significant concentration by one CRO, which represented 90% of the Company’s total prepaid expenses balance.

Property and equipment, net consists of the following (in thousands):

Depreciation expense was $0.8 million for the three months ended  June 30, 2026 and $0.9 million for the three months ended 2025 and $1.7 million for the six months ended June 30, 2026  and $1.8 million for the six months ended June 30, 2025.  There were no impairments of the Company’s property and equipment recorded in the three and six months ended June 30, 2026 and 2025.

Prepaid clinical services, long-term was $25.2 million as of June 30, 2026 and  December 31, 2025. The long-term prepaid clinical services represent amounts the Company has paid to a single CRO as a vendor deposit that will be utilized in more than one year.

Right-of-use assets, net comprises facilities of $10.2 million and $11.4 million as of June 30, 2026 and December 31, 2025, respectively. 

Intangible assets are comprised of developed technology and intellectual property. Intangible assets are carried at cost less accumulated amortization. As of June 30, 2026, developed technology and intellectual property had remaining lives of 3.4 years and 1.5 years, respectively. As of June 30, 2026, there have been no indicators of impairment.

Intangible assets consist of the following (in thousands):

Intangible asset amortization expense was $0.2 million for each of the three months ended June 30, 2026 and 2025 and $0.4 million for each of the six months ended June 30, 2026 and 2025.

As of June 30, 2026, the estimated future amortization expense by year is as follows (in thousands):

Goodwill, which represents the excess of the purchase price over the fair value of assets acquired, was $4.5 million as of  June 30, 2026 and December 31, 2025. As of June 30, 2026, there have been no indicators of impairment.

Accounts payable were $17.0 million and $21.5 million as of June 30, 2026 and December 31, 2025, respectively. As of June 30, 2026, there was a significant concentration by one CRO and one analytical testing vendor, which represented 28% and 58% respectively, of the Company’s total accounts payable balance. As of  December 31, 2025, there was a significant concentration by one CRO and one analytical testing vendor, which represented 66% and 28%, respectively, of the Company’s total accounts payable balance.

Deferred government revenue represents amounts received from HHS BARDA contracts where the earnings process is not yet complete. The Company will recognize deferred government revenue once the earnings process is complete, in accordance with its revenue recognition policies.

The following table represents the Company's deferred government revenue (in thousands):

Amounts collected or invoiced during the six months ended June 30, 2026 and year ended December 31, 2025, primarily relate to amounts received on the 2024 ATI-RRPV Contract (as defined in Note 5), but for which revenue cannot yet be recognized due to contractual milestones not being achieved.

Deferred collaboration revenue represents amounts received from the 2025 License and Collaboration Agreement with Dynavax Technologies Corporation, a Sanofi company ("Dynavax"), entered into in November 2025 (as defined in Note 5), where the earnings process is not yet complete. The Company will recognize deferred collaboration revenue once the earnings process is complete, in accordance with its revenue recognition policies. 

The following table represents the Company's deferred collaboration revenue (in thousands):

Other accrued current liabilities consist of the following (in thousands):

As of June 30, 2026 and December 31, 2025, there was a significant concentration by one CRO, which represented 81% and 79% of the Company’s total other accrued liabilities balances, respectively.